That ignored independent study testing 4 different assays from MRK/BMY/AZN/Roche on same samples presented last year. Concordance among MRK/BMY/AZN assays based on TC was very high, about 90%, but significantly fewer positives by Roche assay, only about 60%. Concordance among all 4 assays based on IC was less than based on TC, but Roche isn't alone compared to the other 3 unlike based on TC. Thus at least it needs caution to generalize clinical trial results based on PD-L1 expression from Roche to the other 3.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.